Topics

Companies Related to "Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease" [Most Relevant Company Matches] RSS

10:32 EST 21st February 2020 | BioPortfolio

Here are the most relevant search results for "Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Nilotinib Steroid Dependent Refractory Chronic Graft Versus" Companies 1–25 of 1,900+

Relevant

DACOGEN

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and i...


Intersect ENT, Inc. '

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new ste...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


Biofrontera AG

Biofrontera AG is a biopharmaceutical company specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The Company has three product candidates in clinical development for four different clinical indications. The most advanced products are BF-200 ALA (Phase IIb/III) for actinic keratosis and condyloma; and BF-derm 1 (Phase II) for chronic, antihistami...

COPD Foundation

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the U.S. and the only chronic disease growing in mortality. It affects approximately 24 million Americans but only 12 million are diagnosed. COPD includes chronic bronchitis, emphysema, and adult onset (refractory) asthma. Symptoms include breathlessness, wheezing, and chr...

Gene Signal

Gene Signal (www.genesignal.com) is developing a robust pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions based on its innovative angiogenesis modulating technology. The company’s most advanced therapeutic product is aganirsen (GS-101), an antisense oligonucleotide that has nearly completed...

Ariad Pharmaceuticals Incorporated

ARIAD Pharmaceuticals, Inc. is focused on the discovery and development of novel and proprietary drugs based on its understanding of the inner-workings of cells and the genes involved in disease. The Company has developed a product based on its gene regulation technology to treat graft-versus-host disease, a complication of bone marrow transplantation involving an attack by a patient's immune syst...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...

Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

Artegraft, Inc.

Incorporated in 1993, Artegraft, Inc. offers surgeons a biological alternative to synthetic grafts. Artegraft’s natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft a...

Taylor Hooton Foundation

The Taylor Hooton Foundation was founded in 2004 after Don Hooton’s son Taylor, an aspiring baseball player, took his own life because of steroid use. The Foundation seeks to inform America’s youth, parents, coaches, professional athletes and organizations about the dangers of steroid use.

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform bas...

Hollis-Eden Pharmaceuticals, Inc.

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule pla...

SIRAKOSS Ltd

SIRAKOSS is developing nanosynthetic graft substitutes to facilitate complete bone repair and transform patient healing. The SIRAKOSS bone graft substitutes utilise advanced and proprietary understanding of nanostructures and nanochemistry to catalyze faster bone regeneration coupled with total graft resorption. SIRAKOSS was spun out of the University of A...

GlycoMimetics, Inc. and Apollomics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical tr...

Polyheal Ltd.

Polyheal Ltd. is pioneering a revolutionary approach by filling the unmet need in the wound management market with a general stimulator of granulation, a major step in the healing process of chronic and acute wounds. Established in 1996, Polyheal is committed to implement its unique proprietary scientific microsphere-based technology to develop, manufacture & commercialize advanced wound healing ...

InnAVasc, Inc.

InnAVasc Medical, Inc. is a medical device company founded by Duke University surgeons and scientists, which designs and develops products for vascular and hemodialysis access. The Company’s first technology is an arteriovenous graft (AVG) modification that incorporates two multilayer cannulation chambers, with self-sealing technology, that are resist...

Gemin X Pharmaceuticals, Inc.

Gemin X Pharmaceuticals, Inc., specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT...

DOR BioPharma

DOR BioPharma, Inc. is a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biomedical countermeasures. Our lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD)...

SanBio Group

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based investigational product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke, a...

Erimos Technologies, LLC

Erimos has exclusive license for nordihydroguaiaretic acid (NDGA) derivatives from The Johns Hopkins University. We have developed a novel process to extract NDGA from the resin of the leaves of Larrea tridentata, a desert plant indigenous to the southwestern US and Mexico. EM-1421, our lead candidate, is a semi-synthetic derivative of NDGA. It is designed to target specific differences between no...

ApaTech, Inc.

ApaTech is a world leader in synthetic bone graft technologies. Our mission is to provide surgeons with superior, proprietary, bone graft solutions, helping them improve clinical outcomes and patient quality of life. ApaTech was formed in 2001 with the rights to bone materials research and IP from London and Cambridge Universities. The company retains pipeline agreements with founding inventors, i...

Ario Pharma Ltd

ario pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease. Co...


More From BioPortfolio on "Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease"

Quick Search

Corporate Database Quicklinks